Table 1. PK of GSK744 in rhesus macaques dosed with GSK744 LA (50 mg/kg).

ND, not determined.

AUC (0−τ)
(μg × hour/ml)
Cτ (μg/ml)Cmax (μg/ml)Tmax (day)*t1/2 (day)
GSK744 LA dose121212122
50 mg/kg (male)2047 (772)2593 (648)‡§2.66 (1.07)‡§2.62 (1.66)4.53 (2.12)5.17 (1.20)‡§14 (7–28)42 (35–56)8.6 (3.7)
50 mg/kg (female),
Depo-Provera–treated (PK study)
1698 (455)1616 (591)1.20 (0.74)1.29 (0.59)4.21 (0.84)3.47 (1.45)10.5 (7–21)38.5 (35–49)ND||
50 mg/kg (female),
Depo-Provera–treated (challenge study)
1247 (236)1587 (415)0.85 (0.51)1.39 (0.75)3.03 (0.71)3.45 (0.98)14 (7–21)42 (35–49)9.6 (7.8)

*Tmax reported in median (range) and not subjected to statistical analyses.

t1/2 estimated for the second dose only because terminal phases were long enough to estimate parameter.

P < 0.05 when compared with female challenge study.

§P < 0.05 when compared with female PK study.

P < 0.05 when compared with female challenge study.

||t1/2 was not estimated for PK study because sufficient time points were not collected to estimate parameter.